Stem definition | Drug id | CAS RN |
---|---|---|
bradycardic agents | 3312 | 155974-00-8 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 4 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.46 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 1.66 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 10.27 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.28 % | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 20, 2019 | PMDA | Ono Pharmaceutical Co., Ltd. | |
April 15, 2015 | FDA | AMGEN INC | |
Oct. 25, 2005 | EMA | Les Laboratoires Servier |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 464.61 | 18.76 | 453 | 7174 | 473973 | 50123524 |
Photopsia | 154.52 | 18.76 | 46 | 7581 | 3920 | 50593577 |
Drug interaction | 128.57 | 18.76 | 154 | 7473 | 199467 | 50398030 |
Torsade de pointes | 105.41 | 18.76 | 46 | 7581 | 11789 | 50585708 |
Electrocardiogram QT prolonged | 104.95 | 18.76 | 76 | 7551 | 51810 | 50545687 |
Bradycardia | 96.63 | 18.76 | 79 | 7548 | 64347 | 50533150 |
Palpitations | 77.85 | 18.76 | 83 | 7544 | 94423 | 50503074 |
Cardiac failure | 73.87 | 18.76 | 73 | 7554 | 75967 | 50521530 |
First trimester pregnancy | 72.13 | 18.76 | 10 | 7617 | 8 | 50597489 |
Syncope | 70.29 | 18.76 | 82 | 7545 | 102920 | 50494577 |
Ischaemic stroke | 63.91 | 18.76 | 36 | 7591 | 15912 | 50581585 |
Cardiac failure chronic | 56.56 | 18.76 | 21 | 7606 | 3542 | 50593955 |
Congestive cardiomyopathy | 54.22 | 18.76 | 23 | 7604 | 5495 | 50592002 |
Chest pain | 53.97 | 18.76 | 96 | 7531 | 176786 | 50420711 |
Crush syndrome | 52.46 | 18.76 | 10 | 7617 | 119 | 50597378 |
Apallic syndrome | 51.00 | 18.76 | 13 | 7614 | 620 | 50596877 |
Myoglobin blood increased | 50.36 | 18.76 | 15 | 7612 | 1278 | 50596219 |
Dizziness | 48.84 | 18.76 | 138 | 7489 | 346231 | 50251266 |
Ventricular fibrillation | 48.26 | 18.76 | 26 | 7601 | 10533 | 50586964 |
Language disorder | 45.57 | 18.76 | 15 | 7612 | 1773 | 50595724 |
Bundle branch block left | 45.22 | 18.76 | 21 | 7606 | 6209 | 50591288 |
Drug effective for unapproved indication | 43.86 | 18.76 | 15 | 7612 | 1994 | 50595503 |
Ventricular tachycardia | 43.40 | 18.76 | 28 | 7599 | 15793 | 50581704 |
Pain | 41.16 | 18.76 | 18 | 7609 | 578885 | 50018612 |
Heart rate decreased | 41.01 | 18.76 | 38 | 7589 | 36459 | 50561038 |
Acute kidney injury | 40.38 | 18.76 | 99 | 7528 | 227959 | 50369538 |
Sensorimotor disorder | 40.14 | 18.76 | 10 | 7617 | 434 | 50597063 |
Pneumobilia | 34.56 | 18.76 | 7 | 7620 | 116 | 50597381 |
Dyspnoea | 33.71 | 18.76 | 167 | 7460 | 547441 | 50050056 |
Sinus bradycardia | 30.53 | 18.76 | 21 | 7606 | 13162 | 50584335 |
Heart rate increased | 30.31 | 18.76 | 47 | 7580 | 77203 | 50520294 |
Genital rash | 30.15 | 18.76 | 8 | 7619 | 447 | 50597050 |
Hyperparathyroidism secondary | 29.16 | 18.76 | 10 | 7617 | 1340 | 50596157 |
Shock haemorrhagic | 28.54 | 18.76 | 17 | 7610 | 8327 | 50589170 |
Visual impairment | 27.43 | 18.76 | 42 | 7585 | 68233 | 50529264 |
Lactic acidosis | 26.89 | 18.76 | 29 | 7598 | 33326 | 50564171 |
Anaemia folate deficiency | 26.13 | 18.76 | 6 | 7621 | 183 | 50597314 |
Hyperphosphataemia | 25.97 | 18.76 | 10 | 7617 | 1861 | 50595636 |
Mitral valve incompetence | 25.26 | 18.76 | 21 | 7606 | 17450 | 50580047 |
Tachycardia | 25.20 | 18.76 | 50 | 7577 | 99713 | 50497784 |
Drug ineffective | 25.14 | 18.76 | 54 | 7573 | 819279 | 49778218 |
Lordosis | 23.85 | 18.76 | 6 | 7621 | 271 | 50597226 |
Third trimester pregnancy | 23.40 | 18.76 | 3 | 7624 | 0 | 50597497 |
Second trimester pregnancy | 23.40 | 18.76 | 3 | 7624 | 0 | 50597497 |
Angina pectoris | 23.30 | 18.76 | 24 | 7603 | 26164 | 50571333 |
Tuberculosis of central nervous system | 23.16 | 18.76 | 6 | 7621 | 305 | 50597192 |
Hypotension | 23.16 | 18.76 | 83 | 7544 | 235386 | 50362111 |
Gastrointestinal tract adenoma | 22.88 | 18.76 | 6 | 7621 | 320 | 50597177 |
Femoral neck fracture | 22.39 | 18.76 | 14 | 7613 | 7476 | 50590021 |
Alopecia | 22.00 | 18.76 | 5 | 7622 | 245042 | 50352455 |
Atrial tachycardia | 21.32 | 18.76 | 9 | 7618 | 2123 | 50595374 |
Oliguria | 21.20 | 18.76 | 14 | 7613 | 8202 | 50589295 |
Serotonin syndrome | 20.82 | 18.76 | 22 | 7605 | 24691 | 50572806 |
Pneumonia fungal | 20.76 | 18.76 | 11 | 7616 | 4309 | 50593188 |
Orthopnoea | 20.53 | 18.76 | 12 | 7615 | 5677 | 50591820 |
Lupus myocarditis | 20.06 | 18.76 | 4 | 7623 | 61 | 50597436 |
Gastric antral vascular ectasia | 19.84 | 18.76 | 6 | 7621 | 538 | 50596959 |
Sinus arrest | 19.80 | 18.76 | 8 | 7619 | 1690 | 50595807 |
Osteochondrosis | 19.41 | 18.76 | 7 | 7620 | 1087 | 50596410 |
Nasopharyngitis | 19.31 | 18.76 | 3 | 7624 | 192924 | 50404573 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure | 245.68 | 19.46 | 191 | 8009 | 79096 | 29487231 |
Bradycardia | 115.80 | 19.46 | 115 | 8085 | 65514 | 29500813 |
Computerised tomogram coronary artery abnormal | 114.83 | 19.46 | 23 | 8177 | 185 | 29566142 |
Hypotension | 108.31 | 19.46 | 193 | 8007 | 194161 | 29372166 |
Photopsia | 89.79 | 19.46 | 29 | 8171 | 1744 | 29564583 |
Cardiac failure chronic | 76.87 | 19.46 | 37 | 8163 | 6430 | 29559897 |
Dyspnoea at rest | 69.47 | 19.46 | 28 | 8172 | 3186 | 29563141 |
Ischaemic cardiomyopathy | 69.27 | 19.46 | 33 | 8167 | 5605 | 29560722 |
N-terminal prohormone brain natriuretic peptide increased | 60.30 | 19.46 | 22 | 8178 | 1910 | 29564417 |
Dyspnoea | 59.75 | 19.46 | 212 | 7988 | 326520 | 29239807 |
Oesophageal obstruction | 57.97 | 19.46 | 15 | 8185 | 406 | 29565921 |
Sinus bradycardia | 56.66 | 19.46 | 37 | 8163 | 11566 | 29554761 |
Torsade de pointes | 52.75 | 19.46 | 29 | 8171 | 6632 | 29559695 |
Bezoar | 52.32 | 19.46 | 16 | 8184 | 803 | 29565524 |
Left ventricular enlargement | 51.47 | 19.46 | 15 | 8185 | 637 | 29565690 |
Ventricular arrhythmia | 50.68 | 19.46 | 25 | 8175 | 4579 | 29561748 |
Electrocardiogram abnormal | 47.55 | 19.46 | 28 | 8172 | 7294 | 29559033 |
Ventricular extrasystoles | 47.45 | 19.46 | 32 | 8168 | 10550 | 29555777 |
Blood pressure systolic decreased | 45.69 | 19.46 | 22 | 8178 | 3822 | 29562505 |
Venous pressure jugular increased | 45.55 | 19.46 | 14 | 8186 | 715 | 29565612 |
Oedema peripheral | 42.92 | 19.46 | 91 | 8109 | 103466 | 29462861 |
Ejection fraction decreased | 41.83 | 19.46 | 35 | 8165 | 15943 | 29550384 |
Base excess decreased | 41.15 | 19.46 | 10 | 8190 | 208 | 29566119 |
Glomerular filtration rate decreased | 41.03 | 19.46 | 30 | 8170 | 11236 | 29555091 |
Cardiomyopathy | 39.97 | 19.46 | 33 | 8167 | 14754 | 29551573 |
Atrial tachycardia | 38.83 | 19.46 | 16 | 8184 | 1925 | 29564402 |
Blood potassium increased | 38.16 | 19.46 | 32 | 8168 | 14619 | 29551708 |
Oxygen consumption decreased | 37.37 | 19.46 | 9 | 8191 | 180 | 29566147 |
Venous pressure jugular decreased | 37.02 | 19.46 | 7 | 8193 | 40 | 29566287 |
Ventricular dysfunction | 36.40 | 19.46 | 18 | 8182 | 3313 | 29563014 |
Dermatitis exfoliative generalised | 35.60 | 19.46 | 17 | 8183 | 2899 | 29563428 |
Pulmonary oedema | 35.38 | 19.46 | 51 | 8149 | 42684 | 29523643 |
Hyperkalaemia | 35.29 | 19.46 | 62 | 8138 | 61330 | 29504997 |
Brain natriuretic peptide increased | 35.11 | 19.46 | 19 | 8181 | 4211 | 29562116 |
Ventricular tachycardia | 35.06 | 19.46 | 37 | 8163 | 22537 | 29543790 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 32.97 | 19.46 | 11 | 8189 | 732 | 29565595 |
Bronchial wall thickening | 32.90 | 19.46 | 12 | 8188 | 1040 | 29565287 |
Urticaria chronic | 32.03 | 19.46 | 7 | 8193 | 89 | 29566238 |
Drug interaction | 31.62 | 19.46 | 123 | 8077 | 197262 | 29369065 |
Acute kidney injury | 30.81 | 19.46 | 150 | 8050 | 265117 | 29301210 |
Angina pectoris | 30.33 | 19.46 | 38 | 8162 | 27812 | 29538515 |
Palpitations | 30.09 | 19.46 | 41 | 8159 | 32563 | 29533764 |
Ventricular enlargement | 29.36 | 19.46 | 9 | 8191 | 455 | 29565872 |
Sinus arrest | 29.19 | 19.46 | 12 | 8188 | 1435 | 29564892 |
Death | 28.32 | 19.46 | 32 | 8168 | 342052 | 29224275 |
Blood creatinine increased | 27.69 | 19.46 | 68 | 8132 | 85034 | 29481293 |
ECG signs of myocardial ischaemia | 27.17 | 19.46 | 7 | 8193 | 186 | 29566141 |
Bronchial hyperreactivity | 26.14 | 19.46 | 11 | 8189 | 1395 | 29564932 |
Left ventricular dilatation | 26.12 | 19.46 | 9 | 8191 | 661 | 29565666 |
Presyncope | 26.11 | 19.46 | 27 | 8173 | 16062 | 29550265 |
Hypertrophy | 25.40 | 19.46 | 8 | 8192 | 443 | 29565884 |
Dyspnoea exertional | 25.16 | 19.46 | 40 | 8160 | 36450 | 29529877 |
Non-compaction cardiomyopathy | 25.09 | 19.46 | 5 | 8195 | 39 | 29566288 |
Tracheal atresia | 24.37 | 19.46 | 4 | 8196 | 8 | 29566319 |
Body mass index increased | 24.21 | 19.46 | 9 | 8191 | 823 | 29565504 |
Eosinophilia | 23.75 | 19.46 | 30 | 8170 | 22131 | 29544196 |
Syncope | 23.33 | 19.46 | 62 | 8138 | 81309 | 29485018 |
Tricuspid valve incompetence | 23.24 | 19.46 | 19 | 8181 | 8375 | 29557952 |
Mean cell haemoglobin decreased | 23.15 | 19.46 | 10 | 8190 | 1351 | 29564976 |
Cardiac ventricular thrombosis | 23.15 | 19.46 | 9 | 8191 | 930 | 29565397 |
Blood chloride increased | 22.01 | 19.46 | 12 | 8188 | 2697 | 29563630 |
Pulmonary function test abnormal | 22.01 | 19.46 | 11 | 8189 | 2071 | 29564256 |
Lichenoid keratosis | 21.57 | 19.46 | 11 | 8189 | 2159 | 29564168 |
Oesophageal haemorrhage | 21.36 | 19.46 | 9 | 8191 | 1144 | 29565183 |
Ventricular fibrillation | 21.18 | 19.46 | 24 | 8176 | 15809 | 29550518 |
Blood luteinising hormone increased | 21.10 | 19.46 | 5 | 8195 | 93 | 29566234 |
Breath sounds abnormal | 20.93 | 19.46 | 15 | 8185 | 5442 | 29560885 |
Low cardiac output syndrome | 20.58 | 19.46 | 7 | 8193 | 494 | 29565833 |
Congestive cardiomyopathy | 20.47 | 19.46 | 16 | 8184 | 6614 | 29559713 |
Cardiac hypertrophy | 20.37 | 19.46 | 8 | 8192 | 850 | 29565477 |
Contraindicated product administered | 20.00 | 19.46 | 25 | 8175 | 18241 | 29548086 |
Carbon dioxide decreased | 19.82 | 19.46 | 9 | 8191 | 1370 | 29564957 |
Blood follicle stimulating hormone increased | 19.74 | 19.46 | 5 | 8195 | 124 | 29566203 |
Diastolic dysfunction | 19.61 | 19.46 | 14 | 8186 | 5050 | 29561277 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 381.36 | 16.62 | 589 | 14421 | 632217 | 63851505 |
Cardiac failure | 293.28 | 16.62 | 244 | 14766 | 132129 | 64351593 |
Bradycardia | 192.08 | 16.62 | 183 | 14827 | 118036 | 64365686 |
Photopsia | 177.32 | 16.62 | 59 | 14951 | 4655 | 64479067 |
Torsade de pointes | 148.29 | 16.62 | 75 | 14935 | 17288 | 64466434 |
Drug interaction | 132.19 | 16.62 | 272 | 14738 | 361811 | 64121911 |
Cardiac failure chronic | 126.69 | 16.62 | 55 | 14955 | 8986 | 64474736 |
Computerised tomogram coronary artery abnormal | 118.83 | 16.62 | 23 | 14987 | 185 | 64483537 |
Hypotension | 110.47 | 16.62 | 261 | 14749 | 380713 | 64103009 |
Palpitations | 83.64 | 16.62 | 112 | 14898 | 104376 | 64379346 |
Sinus bradycardia | 83.52 | 16.62 | 57 | 14953 | 22836 | 64460886 |
Dyspnoea | 79.10 | 16.62 | 353 | 14657 | 718321 | 63765401 |
Electrocardiogram QT prolonged | 77.54 | 16.62 | 94 | 14916 | 79354 | 64404368 |
Ventricular tachycardia | 77.37 | 16.62 | 64 | 14946 | 34201 | 64449521 |
Syncope | 75.30 | 16.62 | 133 | 14877 | 157502 | 64326220 |
Ischaemic cardiomyopathy | 71.73 | 16.62 | 34 | 14976 | 6804 | 64476918 |
Acute kidney injury | 69.72 | 16.62 | 246 | 14764 | 448994 | 64034728 |
N-terminal prohormone brain natriuretic peptide increased | 64.46 | 16.62 | 26 | 14984 | 3533 | 64480189 |
Ventricular fibrillation | 63.32 | 16.62 | 49 | 14961 | 23811 | 64459911 |
First trimester pregnancy | 62.99 | 16.62 | 9 | 15001 | 4 | 64483718 |
Ventricular extrasystoles | 60.06 | 16.62 | 42 | 14968 | 17487 | 64466235 |
Left ventricular enlargement | 57.93 | 16.62 | 16 | 14994 | 668 | 64483054 |
Atrial tachycardia | 57.64 | 16.62 | 24 | 14986 | 3535 | 64480187 |
Chest pain | 56.96 | 16.62 | 151 | 14859 | 235829 | 64247893 |
Congestive cardiomyopathy | 55.83 | 16.62 | 33 | 14977 | 10311 | 64473411 |
Dizziness | 55.42 | 16.62 | 222 | 14788 | 429941 | 64053781 |
Ischaemic stroke | 54.90 | 16.62 | 49 | 14961 | 28986 | 64454736 |
Ventricular arrhythmia | 54.58 | 16.62 | 29 | 14981 | 7386 | 64476336 |
Angina pectoris | 53.46 | 16.62 | 59 | 14951 | 45022 | 64438700 |
Dyspnoea at rest | 53.03 | 16.62 | 27 | 14983 | 6302 | 64477420 |
Pain | 51.18 | 16.62 | 33 | 14977 | 553478 | 63930244 |
Oesophageal obstruction | 50.68 | 16.62 | 15 | 14995 | 804 | 64482918 |
Glomerular filtration rate decreased | 49.34 | 16.62 | 39 | 14971 | 19533 | 64464189 |
ECG signs of myocardial ischaemia | 47.70 | 16.62 | 12 | 14998 | 347 | 64483375 |
Ejection fraction decreased | 47.57 | 16.62 | 45 | 14965 | 28662 | 64455060 |
Bundle branch block left | 46.42 | 16.62 | 29 | 14981 | 10005 | 64473717 |
Crush syndrome | 44.26 | 16.62 | 10 | 15000 | 180 | 64483542 |
Hyperkalaemia | 42.76 | 16.62 | 81 | 14929 | 101048 | 64382674 |
Apallic syndrome | 41.48 | 16.62 | 13 | 14997 | 846 | 64482876 |
Bezoar | 39.57 | 16.62 | 16 | 14994 | 2187 | 64481535 |
Base excess decreased | 37.66 | 16.62 | 10 | 15000 | 359 | 64483363 |
Blood pressure systolic decreased | 37.08 | 16.62 | 24 | 14986 | 8796 | 64474926 |
Venous pressure jugular increased | 36.56 | 16.62 | 13 | 14997 | 1250 | 64482472 |
Brain natriuretic peptide increased | 35.15 | 16.62 | 22 | 14988 | 7611 | 64476111 |
Sinus arrest | 34.36 | 16.62 | 16 | 14994 | 3074 | 64480648 |
Blood potassium increased | 34.30 | 16.62 | 36 | 14974 | 25944 | 64457778 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 34.17 | 16.62 | 12 | 14998 | 1113 | 64482609 |
Body mass index increased | 33.73 | 16.62 | 13 | 14997 | 1566 | 64482156 |
Venous pressure jugular decreased | 33.63 | 16.62 | 7 | 15003 | 84 | 64483638 |
Cardiomyopathy | 33.24 | 16.62 | 35 | 14975 | 25321 | 64458401 |
Language disorder | 33.14 | 16.62 | 15 | 14995 | 2702 | 64481020 |
Mitral valve incompetence | 33.03 | 16.62 | 35 | 14975 | 25503 | 64458219 |
Myoglobin blood increased | 32.98 | 16.62 | 15 | 14995 | 2732 | 64480990 |
Tricuspid valve incompetence | 32.74 | 16.62 | 29 | 14981 | 16974 | 64466748 |
Oxygen consumption decreased | 32.46 | 16.62 | 9 | 15001 | 381 | 64483341 |
Dermatitis exfoliative generalised | 32.26 | 16.62 | 19 | 14991 | 5897 | 64477825 |
Electrocardiogram abnormal | 32.14 | 16.62 | 26 | 14984 | 13455 | 64470267 |
Presyncope | 31.76 | 16.62 | 40 | 14970 | 35049 | 64448673 |
Eosinophilia | 30.70 | 16.62 | 41 | 14969 | 38035 | 64445687 |
Sensorimotor disorder | 30.11 | 16.62 | 10 | 15000 | 783 | 64482939 |
Ventricular enlargement | 29.85 | 16.62 | 9 | 15001 | 514 | 64483208 |
Oedema peripheral | 29.79 | 16.62 | 112 | 14898 | 210205 | 64273517 |
Ventricular dysfunction | 28.93 | 16.62 | 17 | 14993 | 5253 | 64478469 |
Blood creatinine increased | 28.84 | 16.62 | 83 | 14927 | 135699 | 64348023 |
Drug effective for unapproved indication | 28.70 | 16.62 | 15 | 14995 | 3693 | 64480029 |
Pneumobilia | 28.43 | 16.62 | 7 | 15003 | 185 | 64483537 |
Bronchial hyperreactivity | 27.91 | 16.62 | 13 | 14997 | 2499 | 64481223 |
Febrile neutropenia | 27.89 | 16.62 | 5 | 15005 | 187652 | 64296070 |
Rash | 27.61 | 16.62 | 40 | 14970 | 458509 | 64025213 |
Diastolic dysfunction | 27.49 | 16.62 | 20 | 14990 | 8855 | 64474867 |
Osteochondrosis | 27.40 | 16.62 | 11 | 14999 | 1476 | 64482246 |
Mean cell haemoglobin decreased | 27.21 | 16.62 | 15 | 14995 | 4107 | 64479615 |
Urticaria chronic | 26.78 | 16.62 | 8 | 15002 | 443 | 64483279 |
Non-compaction cardiomyopathy | 25.97 | 16.62 | 5 | 15005 | 39 | 64483683 |
Rheumatoid arthritis | 25.24 | 16.62 | 4 | 15006 | 164290 | 64319432 |
Bronchial wall thickening | 24.76 | 16.62 | 11 | 14999 | 1896 | 64481826 |
Orthopnoea | 24.75 | 16.62 | 19 | 14991 | 9115 | 64474607 |
Lactic acidosis | 24.48 | 16.62 | 48 | 14962 | 61362 | 64422360 |
Heart rate decreased | 24.37 | 16.62 | 45 | 14965 | 55022 | 64428700 |
Dyspnoea paroxysmal nocturnal | 24.24 | 16.62 | 11 | 14999 | 1993 | 64481729 |
Dyspnoea exertional | 23.98 | 16.62 | 53 | 14957 | 73677 | 64410045 |
Nasopharyngitis | 23.75 | 16.62 | 8 | 15002 | 196065 | 64287657 |
Sinusitis | 23.71 | 16.62 | 3 | 15007 | 145925 | 64337797 |
Vertigo | 23.38 | 16.62 | 46 | 14964 | 58965 | 64424757 |
Infusion related reaction | 23.14 | 16.62 | 5 | 15005 | 164462 | 64319260 |
Abdominal discomfort | 22.86 | 16.62 | 7 | 15003 | 182315 | 64301407 |
Hypertrophy | 22.67 | 16.62 | 8 | 15002 | 752 | 64482970 |
Completed suicide | 22.63 | 16.62 | 12 | 14998 | 224402 | 64259320 |
Pulmonary function test abnormal | 22.23 | 16.62 | 12 | 14998 | 3152 | 64480570 |
Feeling abnormal | 22.20 | 16.62 | 75 | 14935 | 133527 | 64350195 |
Third trimester pregnancy | 22.10 | 16.62 | 3 | 15007 | 0 | 64483722 |
Second trimester pregnancy | 22.10 | 16.62 | 3 | 15007 | 0 | 64483722 |
Anaemia folate deficiency | 21.88 | 16.62 | 6 | 15004 | 244 | 64483478 |
Pulmonary oedema | 21.68 | 16.62 | 53 | 14957 | 78621 | 64405101 |
Genital rash | 21.63 | 16.62 | 8 | 15002 | 861 | 64482861 |
Alopecia | 21.43 | 16.62 | 6 | 15004 | 165684 | 64318038 |
Cardiac ventricular thrombosis | 21.07 | 16.62 | 9 | 15001 | 1411 | 64482311 |
Joint swelling | 21.02 | 16.62 | 12 | 14998 | 215370 | 64268352 |
Arthralgia | 20.81 | 16.62 | 45 | 14965 | 442215 | 64041507 |
Acute coronary syndrome | 20.72 | 16.62 | 24 | 14986 | 19286 | 64464436 |
Hepatic enzyme increased | 20.33 | 16.62 | 3 | 15007 | 129940 | 64353782 |
Lordosis | 20.25 | 16.62 | 6 | 15004 | 323 | 64483399 |
Oesophageal haemorrhage | 20.13 | 16.62 | 9 | 15001 | 1575 | 64482147 |
Intentional overdose | 20.08 | 16.62 | 56 | 14954 | 89888 | 64393834 |
Hyperparathyroidism secondary | 19.69 | 16.62 | 10 | 15000 | 2320 | 64481402 |
Blood pressure decreased | 19.57 | 16.62 | 54 | 14956 | 86145 | 64397577 |
Drug hypersensitivity | 19.54 | 16.62 | 16 | 14994 | 237799 | 64245923 |
Kyphosis | 19.44 | 16.62 | 10 | 15000 | 2383 | 64481339 |
Musculoskeletal stiffness | 18.92 | 16.62 | 3 | 15007 | 123203 | 64360519 |
Tuberculosis of central nervous system | 18.79 | 16.62 | 6 | 15004 | 415 | 64483307 |
Low cardiac output syndrome | 18.62 | 16.62 | 7 | 15003 | 788 | 64482934 |
Arrhythmia | 18.28 | 16.62 | 39 | 14971 | 52905 | 64430817 |
Haematoma | 18.25 | 16.62 | 36 | 14974 | 46214 | 64437508 |
Blood luteinising hormone increased | 18.17 | 16.62 | 5 | 15005 | 206 | 64483516 |
Gastrointestinal tract adenoma | 18.06 | 16.62 | 6 | 15004 | 470 | 64483252 |
Blood chloride increased | 17.61 | 16.62 | 12 | 14998 | 4791 | 64478931 |
Product prescribing error | 17.11 | 16.62 | 30 | 14980 | 35239 | 64448483 |
Infection | 17.06 | 16.62 | 11 | 14999 | 184869 | 64298853 |
Femoral neck fracture | 17.03 | 16.62 | 15 | 14995 | 8709 | 64475013 |
Cardiac failure acute | 17.01 | 16.62 | 20 | 14990 | 16324 | 64467398 |
Lupus myocarditis | 16.94 | 16.62 | 4 | 15006 | 88 | 64483634 |
International normalised ratio decreased | 16.94 | 16.62 | 14 | 14996 | 7464 | 64476258 |
Heart rate increased | 16.92 | 16.62 | 56 | 14954 | 98619 | 64385103 |
Platelet count decreased | 16.86 | 16.62 | 9 | 15001 | 167702 | 64316020 |
Blood follicle stimulating hormone increased | 16.73 | 16.62 | 5 | 15005 | 277 | 64483445 |
None
Source | Code | Description |
---|---|---|
ATC | C01EB17 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations |
ATC | C07FX05 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations |
ATC | C07FX06 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations |
MeSH PA | D002317 | Cardiovascular Agents |
FDA EPC | N0000191544 | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker |
FDA MoA | N0000191546 | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic heart failure | indication | 48447003 | |
Angina pectoris | indication | 194828000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.45 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361649 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361650 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7879842 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361649 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361650 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7879842 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7361649 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7361650 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7879842 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7867996 | Dec. 12, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7867996 | Dec. 12, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7867996 | Dec. 12, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | April 22, 2022 | NEW PRODUCT |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | Oct. 22, 2022 | PEDIATRIC EXCLUSIVITY |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | April 22, 2026 | INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | Oct. 22, 2026 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 | Ion channel | BLOCKER | IC50 | 5.70 | IUPHAR | DRUG LABEL | |||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 | Ion channel | BLOCKER | UNKNOWN | DRUG LABEL | |||||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 | Ion channel | BLOCKER | IC50 | 5.70 | IUPHAR | DRUG LABEL | |||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Ion channel | EC50 | 5.37 | CHEMBL | |||||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 | Ion channel | EC50 | 5.35 | CHEMBL | |||||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 | Ion channel | EC50 | 5.34 | CHEMBL |
ID | Source |
---|---|
D07165 | KEGG_DRUG |
148849-67-6 | SECONDARY_CAS_RN |
4034416 | VANDF |
C0257190 | UMLSCUI |
CHEBI:85969 | CHEBI |
CHEMBL471737 | ChEMBL_ID |
CHEMBL2145077 | ChEMBL_ID |
D000077550 | MESH_DESCRIPTOR_UI |
DB09083 | DRUGBANK_ID |
2357 | IUPHAR_LIGAND_ID |
7523 | INN_ID |
3H48L0LPZQ | UNII |
132999 | PUBCHEM_CID |
1649479 | RXNORM |
20884 | MMSL |
233849 | MMSL |
d05706 | MMSL |
011156 | NDDF |
011157 | NDDF |
420906000 | SNOMEDCT_US |
421228002 | SNOMEDCT_US |
421692002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-800 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-800 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-810 | TABLET, FILM COATED | 7.50 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-810 | TABLET, FILM COATED | 7.50 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-813 | SOLUTION | 5 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-813 | SOLUTION | 5 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-3309 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 33 sections |